Vir Biotechnology (VIR) EBITDA Margin Growth (5y) (2023 - 2026)

Vir Biotechnology (VIR) EBITDA Margin Growth (5y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Vir Biotechnology 1.28 Bn 1.28 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -44.81 Mn
Dec 31, 2025 617,688.00
Sep 30, 2025 -6.77 Mn
Jun 30, 2025 -968,719.00
Mar 31, 2025 -334,487.00
Dec 31, 2024 555,928.00
Sep 30, 2024 -632,022.00
Jun 30, 2024 -341,131.00
Mar 31, 2024 68,559.00
Dec 31, 2023 2,908.00
Sep 30, 2023 -588,536.00